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Abstract
Patients diagnosed with cancer often undergo considerable psychological distress, and the induction of the 
psychological stress response has been linked with a poor response to chemotherapy. The psychological stress 
response is mediated by fluctuations of the hormones glucocorticoids (GCs) and catecholamines. Binding to 
their respective receptors, GCs and the catecholamines adrenaline/noradrenaline are responsible for signalling a 
wide range of processes involved in cell survival, cell cycle and immune function. Synthetic GCs are also often 
prescribed as co-medication alongside chemotherapy, and increasing evidence suggests that GCs may induce 
chemoresistance in multiple cancer types. In this review, we bring together evidence linking psychological stress 
hormone signalling with resistance to chemo- and immune therapies, as well as mechanistic evidence regarding the 
effects of exogenous stress hormones on the efficacy of chemotherapies. 
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INTRODUCTION
The psychological stress response is designed to facilitate a response to perceived threat in order to 
maintain homeostatic equilibria. In humans, the stress response is controlled by fluctuations in hormonal 
secretions, primarily glucocorticoids and catecholamines, under the control of the hypothalamic-pituitary-
adrenal (HPA) axis and sympathetic nervous system (SNS)[1]. Activation of these systems results in host 
priming responses including vasoconstriction and tachycardia, as well as metabolic catabolism and 
redirection of resources to stressed sites, designed to allow for a “fight-or-flight” response[2]. However, in the 
recent evolution of humans, what promotes the initiation of the stress response has changed dramatically, 
while the actual stress response has not. Modern environmental stressors identified include socioeconomic 
burden, social isolation and negative life events as opposed to life-threatening survival situations. As such 
this presents an evolutional disparity between stimuli and response, where responses designed for a “fight-
or-flight” such as an increase in appetite to fuel increase energy expenditure, are chronically overstimulated. 
This exposure to sustained stress hormone signalling has been linked to an increased risk of diseases such 
as hypertension, immune dysfunction and cancer[3]. The main objective of the present review is to describe 
the available knowledge linking psychological stress hormone signalling with resistance to chemo- and 
immune therapies in human and mouse models. A secondary goal is to discuss the mechanistic evidence 
regarding the effects of exogenous stress hormones on the efficacy of chemotherapies.
GLUCOCORTICOIDS
Glucocorticoids (GCs) are regulated though the HPA axis and function in many roles, including roles in 
the circadian rhythm as well as mediating adaptive responses under the stress system[4]. The glucocorticoid 
cortisol, an important hormone released under stressful conditions, is synthesised from cholesterol in 
the adrenal cortex. It is released when corticotropin-releasing hormone in the hypothalamus triggers the 
anterior pituitary to release adrenocorticotropic hormone, in response to complex stress signalling from 
neurons and somatic cells. This in turn stimulates the release of cortisol by the adrenal cortex. Cortisol 
can then act upon a number of systems to regulate homeostatic mechanisms by binding to its cytoplasmic 
glucocorticoid receptor (GR), present on nearly every cell in the body[5]. Activation of the GR translocation 
to the nucleus where gene activation and transcription can be negatively or positively modulated. The GR 
is able to bind to specific glucocorticoid response elements (GREs) in gene promotor regions of DNA, 
and facilitate biphasic transcriptional activation (transactivation). GRs are also able to interact with 
transcription factors such as AP-1 and NF-κB, inhibiting their transcriptional ability, thus supressing gene 
expression by a mechanism known as transrepression[6]. In this way GC through the GR can regulate a 
number of crucial genes controlling metabolism, survival, and apoptosis[7]. GCs can also suppress immune 
responses and activate anti-inflammatory pathways by downregulating expression of certain interleukins 
(ILs), thus decreasing immune cell numbers and activation. This is thought to be a protective mechanism, 
directing the body’s resources away from non-essential processes[8]. The role of GC as anti-inflammatories 
and their role in suppressing the immune system has been extensively reviewed elsewhere[9]. Synthetic 
corticosteroids are regularly administered to cancer patients alongside conventional chemotherapies to 
combat hypersensitivities and reduce inflammation, as well as acting as antiemetics to relieve nausea and 
vomiting[10]. In lymphoid cells, GC are pro-apoptotic and are regularly used as an anti-cancer therapy, with 
the potent synthetic GC dexamethasone used regularly with success. However, evidence suggests they may 
have opposing effects in some solid tumours, contributing to resistance to chemotherapy [Figure 1].
CATECHOLAMINES
The catecholamines adrenaline (A) and noradrenaline (NA) are produced in the adrenal medulla by 
chromaffin cells and released into circulation when stressors activate the SNS. Neural fibres of the SNS are 
able to release these neurotransmitters into all the major organ systems within seconds, allowing for rapid 
physiological responses. Once released the effects of catecholamines are mediated by α- or β-adrenergic 
receptors (ARs), which exist in subtypes (α1-, α2-, β1-, β2- and β3-) and are distributed throughout 
tissues accordingly. α-adrenergic receptors primarily mediate vasoconstriction and contraction of smooth 
muscle and are present on vascular muscle. β-adrenergic receptors also regulate muscle contraction with 
β1-adrenergic receptors located on myocardial muscle acting to increase blood pressure and heart rate thus 
increasing blood flow to skeletal muscles. β2-adrenergic receptors present on bronchial smooth muscles 
facilitate muscle relaxation and vasodilation and also stimulate glucose metabolism[11]. Activation of 
β-adrenergic receptors stimulates synthesis of cyclic adenosine monophosphate (cAMP) which acts as an 
effector in a range of cellular processes. As a result of cAMP upregulation activation of protein kinase A 
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(PKA) can occur, which in turn allows phosphorylation of a number of PKA-receptive proteins involved 
in cell survival, proliferation and gene transcription. Induction of gene transcription occurs as a result of 
PKA-induced phosphorylation of transcription factors responsible for the transcription of genes promoting 
stress response elements, such as cell differentiation and metabolism[12] [Figure 1].
Mechanisms of the stress response
Stress hormones mediate a wide range of biological processes in the cancer setting, and as such the effects 
of stress hormone signalling on chemotherapies is thought to be due to various mechanisms and dependent 
on the chemotherapeutic agent. The effects of stress hormone signalling on the efficacy of various anti-
cancer treatments is reviewed below.
Taxanes
Taxanes such as Paclitaxel and Docetaxel are widely used chemotherapeutic agents capable of disrupting 
microtubule formation and arresting the cell cycle, in turn inducing apoptosis[13]. Several cancers have 
shown good responses to taxane treatment, however acquired resistance is common following long term 
exposure[13]. Stress hormones have been shown to mediate effects on the cell cycle in breast cancer cells, 
upregulating cyclin-dependent-kinase 1 (CDK-1), which lead to cell cycle progression through the G2/M 
stage. In this way stress hormones can reduce the efficacy of paclitaxel which acts on rapidly proliferating 
cells by inhibiting paclitaxel-induced G2/M arrest[14]. This mechanism has been further corroborated by an 
in vivo study demonstrating that the induction of psychological stress promotes tumour growth in mice 
treated with paclitaxel, negating its anti-tumour effect[15].
It is also proposed that the induction of DNA damage can induce resistance to chemotherapies in breast cancer. 
Following DNA damage, activation of the serine/threonine kinases, ATM (ataxia-telangiectasia mutated) and 
Figure 1. Stress hormone mechanism of action. The HPA signals the release of glucocorticoids. Activation of the GR mediates 
transactivation and transrepression of genes through binding to the GRE, which controls the expression of genes involved in inflammation, 
survival and apoptosis. Stimulation of the SNS promotes the release of catecholamines. Activation of the BADR by adrenaline/
noradrenaline stimulates synthesis of cAMP which in turn activates PKA. Phosphorylation of a number of PKA-receptive proteins involved 
in cell survival, proliferation and gene transcription can then occur. HPA: hypothalamic-pituitary-axis; GR: glucocorticoid receptor; 
GRE: glucocorticoid response element; SNS: sympathetic nervous system; BADR: beta-adrenergic receptor; cAMP: cyclic adenosine 
monophosphate; PKA: protein kinase A
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ATR (ataxia telangiectasia and Rad3-related), termed DNA sensors, may occur[16] [Figure 2]. Furthermore, 
downstream substrate molecules (BRCA1 and 2, NBS, p53, and Chk2) can promote tumorigenesis. Stress 
hormones induce DNA damage through the production of damaging reactive oxygen and nitrogen species 
(ROS/RNS)[17], and exposure to both GCs and catecholamines has been shown to increase levels of ROS/
RNS in breast cancer cell lines[18]. The repair of damaged DNA has also been shown to be affected by stress 
hormones through interference with checkpoint kinase signalling, facilitating circumnavigation of cell cycle 
checkpoints which function to halt the cell and allow for repair[19]. In breast cancer cells treated with stress 
hormones the expression of DNA damage response proteins was upregulated, specifically the Kinase ATR 
which initiates a signalling cascade activating p21 to halt the cell cycle. This allows the cell time to repair the 
damaged DNA. The CDK inhibitor p21 functions to inhibit progression into the S phase of the cell cycle, 
and it is proposed that the arrest of cells caused by the addition of stress hormones prevents the action of 
chemotherapies such as paclitaxel that act on dividing cells[15]. The effects of GCs specifically on cell cycle 
arrest and the subsequent effect on cytotoxic anti-cancer treatments is reviewed extensively in[20]. GCs can 
also affect p53, indeed restraint stress decreased levels and function of p53 in mice and promoted the growth 
of human xenograft tumors in a p53-dependent manner[21]. P53 induced P21, Noxa and the pro-apoptotic 
gene PUMA were all decreased in response to restraint stress. The same group showed that this mechanism 
occurred through induction of serum- and glucocorticoid-induced protein kinase (SGK1), which in turn 
increases MDM2 activity and decreases p53 function potentially leading to DNA damage.
Several mechanisms have been proposed to explain the development of resistance to paclitaxel, including 
overexpression of multi-drug resistance (MDR) genes such as MDR-1, which encodes for a membrane 
transporter (P-glycoprotein) that can transport chemotherapeutics such as paclitaxel out of cells[22]. 
Adrenaline was shown to upregulate multi-drug resistance 1 (MDR-1) in breast cancer cells, and reduce 
sensitivity to paclitaxel through a reduction of accumulation of the drug within the cell. In a mouse model 
of psychological stress the concentrations of both cortisol and noradrenaline were increased in the plasma, 
and MDR-1 was significantly expressed in the primary tumour after 26 days. Tumour regression induced 
by doxorubicin treatment was further abolished by the induction of psychological stress, and this was 
reversible by knockdown of MDR-1[23]. These findings were corroborated in a further study using colon 
adenocarcinoma cells. Stimulation of the β-adrenergic receptor by adrenaline increased expression of 
MDR-1 and function of P-glycoprotein, and enhanced chemoresistance to 5-fluorouracil treatment[24]. 
Figure 2. DNA damage response. DNA damage induced by stress hormones activates the DNA damage sensors ATM and ATR, which 
initiate downstream signal cascades controlling DNA repair, cell cycle arrest and apoptosis. ATM: ataxia-telangiectasia mutated; ATR: 
ataxia telangiectasia and Rad3-related
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Administration of GCs in vitro have been shown to induce resistance to chemotherapies. In xenograft 
models of breast and ovarian cancer, pre-treatment with dexamethasone inhibited the therapeutic efficacy 
of paclitaxel and allowed tumour growth to continue[25]. It was hypothesised that GCs may prevent cells 
entering an apoptotic pathway after mitotic arrest, and as such interfere with chemotherapy-induced 
apoptotic cell death[26]. 
However, little was understood about the mechanism by which GCs may exert anti-apoptotic effects 
in cancer cells challenged by chemotherapy. Activation of the GR has previously been shown promote 
cell survival signalling pathways and inhibit pro-apoptotic signalling in mammary epithelial cells[27,28]. 
Additional experiments revealed stimulation of the GR by dexamethasone prior to chemotherapy was able 
to reduce the cytotoxic potential of common chemotherapeutic agents including paclitaxel and doxorubicin 
in breast cancer cell lines[29]. It is proposed that activation of the GR induces expression of serum/
glucocorticoid regulated kinase 1 (SGK-1), which protects cells from chemotherapy-induced apoptosis, and 
this was shown to be reversible by blockade of the GR[30].
Further investigation into molecular signalling downstream of the GR revealed GCs may also contribute 
to cell survival through interference with mitogen-activated protein kinase (MAPK) signalling[31]. MAPK 
activation can be induced by chemotherapy agents and leads to rapid induction of apoptosis. In this study 
paclitaxel was shown to induce MAPK signalling and subsequent apoptosis in breast cancer cells. However, 
MAPK phosphatase-1 (MKP-1), an inactivator of MAPK has been shown to be transcriptionally regulated 
through activation of the GR. Pre-treatment with dexamethasone rapidly induced MKP-1, which was able 
to inhibit MAPK signalling and promote cell survival.
Drawing together these two anti-apoptotic mechanisms, and to confirm the effect of GCs on the 
regulation of anti-apoptotic genes, the expression of SGK-1 and MKP-1 was evaluated in a clinical setting 
in ovarian cancer patients[32]. One dose of dexamethasone was administered to patients during intra-
operative biopsies, and samples of tumour collected pre and post infusion. Treatment with dexamethasone 
significantly increased the expression of SGK-1 and MKP-1 in ovarian tissue compared to control samples. 
This finding was in concurrence with the in vitro data obtained from ovarian cancer cell lines, which 
showed that expression of both SGK-1 and MKP-1 was rapidly induced by activation of the GR and could 
be reversed through GR blockade. Importantly this finding revealed that clinically relevant pharmacological 
doses of dexamethasone had significant effects on the expression of anti-apoptotic genes in tumour tissue, 
which may persist during chemotherapy, potentially reducing the efficacy of treatments.
In another study of Triple Negative Breast Cancer (TNBC) resistance to paclitaxel was also induced by 
activation of the GR, and this was shown to occur as a result of activation of the transcription co-activator 
YAP. The GC mediated activation of YAP also promotes the expansion of cancer stem cells (CSCs), which 
are both highly metastatic and often resistant to chemotherapy[33]. The effects of GC on paclitaxel resistance 
are summarised in Figure 3.
Platinum-based therapies
Other treatments for cancer include platinum-based chemotherapies, a class of agents used in the 
treatment of nearly half of all cancers. The most commonly used drugs include cisplatin, carboplatin and 
oxaliplatin and are used against ovarian, testicular, bladder and colon cancers amongst others[34]. Platinum-
based therapies exert their effects through induction of apoptosis by cross-linking purine bases on DNA, 
interfering with DNA repair mechanisms and inducing irreparable DNA damage. However, resistance to 
platinum therapies is a major problem, and is thought to arise as a result of alteration to platinum transport 
mechanisms, DNA repair processes or apoptotic signalling[34]. 
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Stimulation of the adrenergic response has been shown to have adverse effects on the progression of 
ovarian cancer[35]. In ovarian carcinoma cells, catecholamines were able to reduce the efficacy of cisplatin 
and paclitaxel by inhibition apoptosis, and this effect could be modulated through inhibition of the 
β-adrenergic receptor[36]. Mechanistically, catecholamines induced the expression of DUSP1, a MAPK 
phosphatase linked to the promotion of chemoresistance[37], through direct action of the β-2 adrenergic 
receptor on the promoter, which in turn protects ovarian cancer cells from apoptosis. In a xenograft model 
of ovarian cancer, stimulation of the adrenergic response by restraint stress significantly increased tumour 
burden and the expression of DUSP1. Restraint stress combined with docetaxel significantly impaired the 
efficacy of docetaxel and reduced docetaxel-induced apoptosis, and this could be negated by blockade of 
the β-AR. Knockdown of DUSP1 expression in a subsequent ovarian cancer xenograft model significantly 
restored the efficacy of chemotherapy - indicating that the DUSP1 expression induced by adrenergic 
activation has a functional role in the protection from apoptosis. The findings highlight a potential use for 
pharmacological inhibition of the β-AR using β-blockers to improve the efficacy of chemotherapy in the 
treatment of ovarian cancer patients, who report in significantly higher levels of symptoms associated with 
chronic stress[38]. β-blockers have been used successfully in the treatment of multiple cancers for many 
years, and more recently have been shown to correlate with increased overall survival in patients with 
ovarian cancer[39].
Activation of the GR has also been shown to promote cell survival signalling in high grade serous ovarian 
carcinoma cells and inhibit carboplatin-induced cell death. Subsequent antagonism of the GR using an 
inhibitor was able to enhance the effect of platinum-based chemotherapy on tumour growth in a xenograft 
model of ovarian carcinoma[40]. In another model of ovarian carcinoma, the cytotoxic effects of cisplatin 
were also reduced by treatment with the synthetic glucocorticoid dexamethasone, which inhibited 
cisplatin-mediated apoptosis. It was hypothesised that dexamethasone may increase the adhesive ability 
of ovarian carcinoma cells, and indeed dexamethasone was shown to upregulate the expression of certain 
integrins which play a key role in regulating adhesion to the extracellular matrix (ECM). Inhibition of 
integrin signalling was able to reverse the protective effect of dexamethasone and restore the efficacy of 
chemotherapeutic treatment[41].
Stimulation Inhibition
Figure 3. Glucocorticoids and chemoresistance. Glucocorticoids can reduce the efficacy of chemotherapeutics (taxanes and platinum-
based drugs) through upregulation of cell survival signalling, downregulation of apoptosis and interference with DNA repair mechanisms 
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Similar results with GCs have been observed in cell lines representing TNBCs. Dexamethasone was able to 
decrease sensitivity to cisplatin, as well induce expression of Krüppel-like factor 5 (KLF5), a transcription 
factor that has been shown to promotes survival and proliferation in basal breast cancers[42]. Furthermore, 
the induction of KLF5 contributed to dexamethasone mediated chemoresistance in vivo. Dexamethasone 
treatment promoted resistance to docetaxel, whereas KLF5-knockdown cells formed tumours that were 
sensitive to docetaxel even in the presence of dexamethasone[42]. Dexamethasone induced cisplatin 
resistance via KLF-5 to promote cell proliferation can occur via many mechanisms including through 
regulation of cyclin D, fibroblast growth factor binding protein 1, microsomal prostaglandin E2 
synthase[43-45]. 
In the treatment of cervical cancer, GCs may also play a role in response to therapy. Infection with certain 
strains of human papillomavirus (HPV) is strongly linked to an increased risk of cervical cancer. It is 
though that this occurs as a result of viral oncoproteins interfering with the normal functioning of the 
tumour suppressor p53. In HPV-positive cervical cancer cells glucocorticoids not only downregulated p53, 
but also a microRNA (miR-145) associated with tumour suppression and shown to be downregulated in 
cervical cancer tissues. The downregulation of miR-145 by cortisol correlated with an increase in resistance 
to the antitumor drug mitomycin C, and this was shown be a direct result of glucocorticoid-mediated 
expression of a viral oncoprotein[46].
However, dexamethasone has also been shown to enhance the cytotoxicity of cisplatin in cervical cancer 
cells, through the inhibition of the transcription factor nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB)[47]. NF-κB is an important signal transducer that regulates certain apoptotic 
signalling processes, and inactivation of NF-κB can therefore promote apoptosis. In breast cancer cells a 
similar result was also observed, with glucocorticoid treatment inhibiting activation of NF-κB, promoting 
apoptosis and increasing chemosensitivity[48]. This directly contradicts another mechanism suggested by 
Fan et al.[26] which suggests that paclitaxel promotes the release and translocation of NF-κB, which acts on 
apoptosis-related gene expression, promoting cell death. GCs meanwhile upregulate the expression of an 
inhibitor of NF-κB, which prevents this, leading to chemoresistance . These conflicting arguments therefore 
indicate that the effect of glucocorticoids on chemotherapy- induced apoptosis mediated by NF-κB is 
largely dependent on the cell type and stimulus.
Herr et al.[49] also investigated the effects of GCs on solid cancer cell lines alongside lymphoid cells. Human 
lung and cervical cancer carcinoma cells were implanted as xenografts, and weekly does of cisplatin 
were given alongside dexamethasone added to the drinking water. It was subsequently observed that 
dexamethasone inhibits the efficacy of cisplatin cytotoxicity in the lung cancer xenograft model, and 
this was replicated in vitro in a human cervical cancer line. Blockade of the GR using RU486 was found 
to significantly reverse the GC-mediated reduction of apoptosis. The induction of apoptotic signalling 
by chemotherapy agents and irradiation is mediated by caspase cleavage and the cross-linking of death 
receptors. On a mechanistic level, treatment with dexamethasone interfered with key apoptotic molecules 
induced by cisplatin, downregulating caspase-8 and caspase-9, as well as death receptor ligands CD95-L 
(Fas ligand) and TRAIL. In a later study this result was corroborated, with dexamethasone inhibiting 
TRAIL-induced apoptosis in thyroid cancer cells[50]. The opposite effect was observed in lymphoid cells, 
indicating the anti-apoptotic effects of GCs are specific to solid tumours. Over-expression of caspase-8 
and 9 was able to sensitise dexamethasone treated lung carcinoma cells to cisplatin in vivo, significantly 
reducing tumour growth compared to dexamethasone/cisplatin treated. Furthermore, in hepatic cells, 
Yang and colleagues have shown that dexamethasone can negatively affect cisplatin induced apoptosis by 
increasing anti apoptotic genes BCL-2 and BCL-xl[51].
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In a lung carcinoma cell line cell treated with cisplatin and dexamethasone, not only were the cells protected 
from apoptosis, they were able to recover and continue to proliferate after 3 weeks[52]. Dexamethasone also 
inhibited cisplatin-induced apoptosis and promoted cell growth in a panel of ovarian[53] and pancreatic[54] 
cancer cell lines, and similar results were observed with gemcitabine and dexamethasone co-treatment. 
In primary ovarian cancer cells isolated from fresh surgical samples or pleural effusions, dexamethasone 
prevented cell death and increased viability of cells treated with chemotherapeutics and γ-irradiation. 
The same effect was also observed in primary tumour cells isolated from pancreatic carcinomas. When 
implanted in vivo treatment with dexamethasone negated the therapeutic effect of cisplatin, promoting 
rapid growth of the pancreatic and ovarian cancer xenografts. Taken together it is likely that dexamethasone 
can negatively affect the efficacy of cisplatin via the GR with effects on both cell proliferation (KLF-5) and 
apoptotic mechanisms, e.g., elevation of anti-apoptosis genes by dexamethasone. 
Anthracyclines 
Doxorubicin is a non-selective anthracycline widely used in the treatment of breast, bladder and ovarian 
cancer as well as types of leukaemia and lymphoma, often in combination with other therapies[55]. The 
cytotoxic effects of Doxorubicin are mediated through multiple mechanisms; the intercalation of DNA 
which forms doxorubicin-DNA adducts that induce cell death, and the disruption of topoisomerase-II 
activity, thereby preventing DNA resealing and subsequently preventing replication in rapidly dividing 
cells[56]. Furthermore, the oxidization of Doxorubicin to a semi-quinone by NAD(P)H-oxioreductases 
also generates free radicals increasing oxidative stress and promoting protein, lipid and DNA damage[55,57]. 
Although highly effective, and considered a mainstay of chemotherapy regimens, Doxorubicin treatment 
also triggers many side effects including acute cardiotoxicity[58], vomiting, hair loss and inflammation[57]. As 
such it is often prescribed alongside dexamethasone to treat hypersensitivity. 
Resistance to doxorubicin poses a significant problem in the treatment of aggressive breast cancers, and 
since there is currently no marker to predict the efficacy of Doxorubicin, it is often prescribed without a full 
understanding of the therapeutic gain[59]. Resistance to Doxorubicin has been associated with a number of 
factors related to its mechanisms of action, including MDR-associated proteins, alterations in DNA repair 
and topoisomerase activity and increased detoxification capacity[57,60,61]. The ability of a cell to increase 
protection from oxidative stress is particularly relevant in the context of Doxorubicin resistance as oxidative 
stress plays a role in its mechanism of action. An increase in intracellular reduced glutathione which has 
anti-oxidant capacities has been observed in cells with reduced Doxorubicin sensitivity[62]. Furthermore, 
studies have positively correlated expression of genes associated with increase antioxidant capacity with 
chemoresistance - with particular focus on nuclear factor erythroid 2-related factor (NRF2), a transcription 
factor that controls cellular redox homeostasis and detoxification by regulating several antioxidant response 
related genes[63]. 
Expression of NRF2 is upregulated in several cell lines resistant to chemotherapy drugs including cisplatin 
and etoposide, as well as Doxorubicin resistance breast cancer lines, and its inhibition is capable of 
restoring sensitivity[63,64]. Tamoxifen resistance was also reversed by the blockade of NRF2 in an MCF-7 
derived cell line which possessed an enhanced antioxidant expression profile[65]. Furthermore, the inhibition 
of downstream targets of NRF2 such as heme oxygenase-1 (HO-1) have been shown to be able to decrease 
cell viability in leukaemia cells[66]. In NRF2 knockout mice studies showed an increased susceptibility to 
tumour formation in response to exposure to carcinogens[67], supporting the current consensus that the 
NRF2 pathway functions a cell survival pathway protecting against oxidative stress that can be deregulated 
in tumourigenic transformation.
 
GCs have been shown promote cell survival signalling pathways in mammary epithelial cells[27] and reduce 
the cytotoxic potential of common chemotherapeutic agents in breast and ovarian cancer cell lines[29,41]. 
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Multiple mechanisms have been proposed to explain the pro-survival effects of GCs including increased 
cell adhesion and inhibition of apoptosis via the induction of anti-apoptotic proteins[41,68]. Dexamethasone 
has also been shown to modulate immunological effects in patients receiving chemotherapy, increasing the 
activation of regulatory T cells which are capable of suppressing anti-tumour responses[69]. Dexamethasone 
has been show to mediate conflicting effects on Doxorubicin specifically, acting as a chemosensitiser in vivo 
enhancing the inhibition of tumour growth by Doxorubicin[48], and promoting chemoresistance in cancer 
cell lines and models[49].
GCs are also known to play a role in oxidative stress in cancer. Through genomic and non-genomic 
pathways the GR is involved in the transactivation and transrepression of multiple anti-inflammatory 
responses that suppress oxidative stress[70]. Activation of the GR can inhibit NRF2 activity through 
repression of transcription of the NRF2 gene, and subsequently suppress the antioxidant response 
including the expression of antioxidant response controlled genes[71]. Conversely GCs have also been 
shown to increase levels of damaging free radicals in the context of breast cancer in a rapid non-genomic 
manner[18]. In this way, GCs may serve to increase oxidative stress which can promote decreased sensitivity 
to Doxorubicin through upregulation of the antioxidant response. In addition, GC-increases in oxidative 
stress may lead to low levels of DNA damage, decreases on DNA repair mechanisms and genome instability 
leading to a pro survival phenotype.
STRESS AND DNA REPAIR MECHANISMS 
Alterations to DNA repair mechanisms are known to strongly influence the acquisition of resistance 
to many therapies including platinum-based therapies, due to the need for recognition and removal of 
platinum-DNA adducts. Activation of the DNA repair machinery slows down or halts the transition of 
cells through the cell cycle, and as such the ability of cells to repair the damaged DNA dictates sensitivity 
or resistance to platinum-based drugs[72]. Cortisol and noradrenaline have not only been shown to induce 
DNA damage, but also affect DNA repair[19,73]. In precancerous 3T3 cells, we have shown that stress 
hormones decrease UV induced DNA repair as measured by the comet assay. The addition of stress 
hormones increased the expression of DNA damage response proteins Chk1 and Chk2, as well as CDC25a, 
a member of the CDC25 family, levels of which would be expected to decrease in response to damage. 
Both GC and NA have been shown to reduce the rate of DNA repair in TNBC; cells treated with cortisol 
and assessed for DNA damage after a 20 minute repair period showed high levels of DNA damage inferring 
a lack of repair[18]. These effects may represent further possible mechanisms by which stress hormones may 
contribute to resistance to platinum-based therapies.
ADRENERGIC STRESS AND IMMUNE THERAPIES
Recent animal studies have focused the attention on adrenergic stress effects on the efficiency of immune 
therapies. In particular, the role of stress on immune checkpoint therapy and on the immune tumour 
microenvironment has been shown using syngeneic models of breast cancer and melanoma. In this study, 
mice were exposed to mild, chronic cold stress and housed at 22 °C instead of 30 °C, causing the activation 
of the adrenergic signaling pathway. To block the adrenergic signaling, mice were treated with propranolol, a 
non-selective β-blocker. The stress effect on the immune response against cancer was assessed by evaluating 
the adaptive cell-mediated immune response. In particular, the presence of active CD8+ T cells was assessed 
in the tumour of stressed mice as well as the ratio between IFN-γ+ CD8+ and CD4+ cells. The tumour 
microenvironment was also studied considering the cancer-mediated immunosuppression via PD-1/PD-L1 
interaction and mice were treated with a PD-1/PD-L1 inhibitor. Cold-stressed mice undergoing a treatment 
with propranolol showed a reduced tumour growth and an enhanced CD8+ T cell-mediated tumour 
immune response compared to control group housed at standard temperature. Moreover, PD-1 expression 
was increased in CD8+ tumour infiltrating lymphocytes (TILs) of cold-stressed mice with a decrease in the 
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frequency in the propranolol treated group. This finding suggests that PD-1 signalling is one of the routes 
used by the adrenergic stress to cause immunosuppression in the tumour microenvironment and PD-1 
blockade is significantly improved when cold-stressed mice are treated with propranolol[74]. Taken together, 
these results show that adrenergic stress has an effect in shaping the T cell phenotype in the context of 
tumour microenvironment. Also, the pharmacological blockade of the adrenergic stress signaling pathway 
improves to gain a pro-inflammatory effector phenotype (IFN-γ+CD8+) and reduces the anergy phenotype 
(PD-1high). For these reasons, a strategic treatment with a combination of propranolol and immune 
therapies such as PD-1/PD-L1 inhibitors has potential.
  
The influence of β-adrenergic signalling on T-cell targeting immune therapies was also shown in a 
mouse model of lymphoma. In this study, mice treated with isoprenaline, a non-selective β-adrenergic 
agonist, showed an acceleration in the growth of lymphoma which was reversed when the treatment was 
administered in mice not expressing β-adrenergic receptors (β1β2AR-KO). The effect on immune therapies 
was evaluated by treating mice with monoclonal antibodies against 4-1BB and PD-1 showing a significant 
inhibition of lymphoma growth in the 4-1BB treated group. However, when mice were also treated with 
isoprenaline both α4-1BB and αPD-1 immune therapies were less effective. To further investigate the effect 
on the cell-mediated response, mice received tumour specific CD8+ T cells with adoptive transfer prior 
tumour inoculation and the functional status of these cells was assessed after the isoprenaline and immune 
treatments. Isoprenaline significantly decreased the IFN-γ production and the cytotoxicity that T cells 
acquired with the α4-1BB treatment[75].
Figure 4. Stress hormone-mediated immune regulation. Glucocorticoids immune regulation is associated with the blockade of the pro-
inflammatory gene expression. GCs bind the cytoplasmic glucocorticoid receptors (GRs) and translocate to the nucleus where they inhibit 
transcriptional factors such as NF-κB or AP-1 that regulate the expression of pro-inflammatory genes. Catecholamines can bind G-protein 
coupled adrenergic receptors on the membrane of immune T cells. The adrenergic signalling pathway blocks the production of the pro-
inflammatory cytokine IFN-γ and consequently B cell production of IgG2a. On the contrary, β-adrenergic signalling is not thought to affect 
Th2 cells producing of IL-4 or B cells producing IgG1. Both GCs and the adrenergic hormones affect the T cell migration by regulating the 
T cell cytoskeleton and actin-binding proteins such as moesin. This leads to the hypothesis that stress hormones can have a role in the T 
cell trafficking into the tumour. Furthermore, stress hormones exposure correlates with the loss of the activation immune marker CD43.
GCs: glucocorticoids; GRs: glucocorticoid receptors
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Although these first studies confirm the idea that adrenergic stress weakens the efficacy of immune 
therapies by inhibiting the pro-inflammatory and anti-tumour response more work is necessary for a better 
understanding of the molecular mechanisms modulating the immune response against cancer. It is known 
that stress affects the cell-mediated immunity by regulating T cell subtypes and activation status. However, 
the literature is deficient in addressing some important aspects of the stress effect in cancer immunity that 
can undermine the immunotherapy potential. For instance, the efficacy of immunotherapies such as PD-1 
and PD-L1 inhibitors is correlated with the immune infiltration (TILs) status of the tumour. In a study 
on metastatic melanoma, tumours from patients with high TILs, also known as “hot tumours”, showed a 
higher PD-L1 expression and a better outcome[76]. This consideration leads to the hypothesis that T cell 
infiltration into the tumour represents an indication of how successful the immunotherapy is likely to be. 
Since stress hormones modulate T cell migration, stress can also have a role in the T cell trafficking and 
infiltration into the tumour. As a final consideration, stress can affect the immune response directly or 
indirectly by affecting the tumour itself. In this much more complex scenario stress can create an immune 
hostile tumour microenvironment or regulate the tumour escape process. For these reasons, the role of 
stress on tumour growth, spread and angiogenesis has an important impact on how it can cooperate in 
undermining the tumour immune response and the efficacy of immunotherapies [Figure 4].
CONCLUSION
Identification of the role of stress hormone signalling in cancer drug resistance highlights the need for greater 
understanding of biobehavioural factors in the treatment of cancers. Furthermore, the use of interventions 
including stress hormone receptor antagonism by both well-characterised and novel inhibitors may provide 
useful tools to complement current therapeutic strategies. Research into better anti-emetic therapies to 
reduce the use of synthetic glucocorticoids as co-treatments may also prove beneficial. 
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